Prolactin disorders

Fertility and Sterility

Volumn 67, Issue 2, 1997, Pages 215-225

  Yazigi, Ricardo A ^a   Quintero, Carlos H ^a   Salameh, Wael A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prolactin; prolactin secreting adenomas; reproduction

Indexed keywords

ENDOCRINE DISEASE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; INFERTILITY; MALE SEXUAL DYSFUNCTION; MENSTRUATION DISORDER; OVULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; REPRODUCTION; REVIEW; TREATMENT PLANNING;

EID: 0031037534     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)81900-0     Document Type: Article

References (100)

1. Owerback D, Rutter WJ, Cooke NE, Martial JA, Shows TB. The prolactin gene is located on chromosome 6 in humans. Science 1981;212:815-6.
2. Elsholtz HP. Molecular biology of prolactin: cell-specific and endocrine regulators of the prolactin gene. Semin Reprod Endocrinol 1992;10:183-95.
3. Clements J, Whitfield P, Cooke N, Healy D, Matheson B, Shine J, et al. Expression of prolactin gene in human decidua-chorion. Endocrinology 1983;112:1133-4.
4. Gellersen B, Bonhoff A, Hunt N, Bohnet HG. Decidual-type prolactin expression by the human myometrium. Endocrinology 1991;129:158-68.
5. DiMattia GE, Gellersen B, Duckworth ML, Friesen HG. Human prolactin gene expression: the use of an alternative non-coding exon in decidua and the IM-9-P3 lymphoblast cell line. J Biol Chem 1990;256:16412-21.
6. Asa SL, Penz G, Kovaks K, Ezrin C. Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med 1982;106:360-3.
7. Shome B, Parlow AR. Human pituitary prolactin (hPRL): The entire linear amino acid sequence. J Clin Endocrinol Metab 1977;45:1112-5.
8. McNatty KP. Relationship between plasma prolactin and the endocrine microenvironment of the developing human antral follicle. Fertil Steril 1979;32:433-8.
9. Golander A, Hurley T, Barret J, Hizi A, Handwerger S. Prolactin synthesis by human chorion-decidual tissue: a possible source of prolactin in the amniotic fluid. Science 1978; 202:311-3.
10. Maslar IA, Riddick DH. Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1979;135:751-4.
11. Forsyth IA. Variation among species in the endocrine control of mammary growth and function: the role of prolactin, growth hormone, and placental lactogen. J Dairy Sci 1986; 69:886-903.
12. Brumsted JR, Riddick DH. Prolactin and the human menstrual cycle. Semin Reprod Endocrinol 1992;10:220-7.
13. Josimovich JB, Merisko K, Bocella L. Amniotic prolactin control over amniotic and fetal extracellular fluid water and electrolytes in the rhesus monkey. Endocrinology 1977; 100:564-70.
14. Handwerger S, Harman I, Golander A, Handwerger DA. Prolactin release from perifused human decidual explants: effects of decidual prolactin-releasing factor (PRL-RF) and prolactin release-inhibitory factor (PRL-IF). Placenta 1992; 13:55-62.
15. Rosenberg SM, Maslar IA, Riddick DH. Decidual production of prolactin in late gestation: further evidence for a decidual source of amniotic fluid prolactin. Am J Obstet Gynecol 1980;138:681-5.
16. Catt KJ, Dufau ML. Gonadotropic hormones: biosynthesis, secretion, receptors, and actions. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology. 3rd ed. Philadelphia: W.B. Saunders, 1991:105-55.
17. Yen SSC. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology. 3rd ed. Philadelphia: W.B. Saunders, 1991:357-88.
18. Lobo RA, Kletzky OA, Kaptein EM, Goebelsman U. Prolactin modulation of dehydroepiandrosterone sulfate secretion. Am J Obstet Gynecol 1980;138:632-6.
19. Lewis UJ, Singh NRP, Lewis LJ. Two forms of glycosilated human prolactin have different pigeon crop sac-stimulating activities. Endocrinology 1989;124:1558-63.
20. Shoupe D, Montz FJ, Kletzky OA, diZerega GS. Prolactin molecular heterogeneity. Am J Obstet Gynecol 1983;147: 482-7.
21. Heffner LJ, Gramates LS, Yuan LW. A glycosilated prolactin species is covalently bound to immunoglobulin in human amniotic fluid. Biochem Biophys Res Commun 1989;165: 299-305.
22. Farkouh NH, Packer MG, Frantz AG. Large molecular PRL with reduced receptor activity in human serum: high proportion in basal state and reduced after TRH. J Clin Endocrinol Metab 1979;48:1026-32.
23. Foord SM, Peters JR, Dieguez C, Scanlon MF, Hall R. Dopamine receptors in intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. Endocrinology 1983;112:1567-77.
24. Melis GB, Paoletti AM, Mastrapasqua NM, et al. The effects of the GABAergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 1982;54:485-9.
25. Jacobs LS, Snyder PJ, Wilbur JF, Utiger R, Daughaday WH. Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab 1971;33:996-8.
26. Clemens JA, Roush ME, Fuller RW. Evidence that serotonin neurons stimulate secretion of prolactin releasing factor. Life Sci 1978;22:2209-13.
27. Kato Y, Iwasaki Y, Iwasaki J, Abe H, Yanaihara N, Imura H. Prolactin release by vasoactive intestinal polypeptide in rats. Endocrinology 1978;103:554-8.
28. Carlson HE. Prolactin stimulation by protein is mediated by amino acids in humans. J Clin Endocrinol Metab 1989; 69:7-14.
29. Parker DC, Rossman LG, Vanderlaan EF. Relation of sleep-entrained human prolactin release to REM-nonREM cycles. J Clin Endocrinol Metab 1973;38:646-51.
30. Rigg LA, Lein A, Yen SSC. Pattern of increase of circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977;129:454-6.
31. Rigg LA, Yen SSC. Multphasic prolactin secretion in human subjects. Am J Obstet Gynecol 1977;128:215-8.
32. Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 1972;35:840-51.
33. Gregerson KA, Selmanoff M. Selection effects of hyperprolactinemia on in vitro dopamine release from median eminence synaptosomes. J Neurol Sci 1988;8:2477-84.
34. Schettini G, Cronin MJ, Mac Leod RM. Adenosine 3′5′-monophosphate (cAMP) and calcium-calmodulin interrelation in the control of prolactin secretion: evidence for dopamine inhibition of cAMP accumulation and prolactin release after calcium mobilization. Endocrinology 1983;112:1801-7.
35. Molitch ME, Reichlin S. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions in the hypothalamus and pituitary stalk. In: MacLeod RM, Thorner MO, Scapagnini U, editors. Prolactin: basic and clinical correlates. Padova: Liviana Press, 1985:709-19.
36. Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab 1984;59:941-8.
37. Quigley ME, Judd SJ, Gilliland GB, Yen SSC. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation. J Clin Endocrinol Metab 1979;48:718-20.
38. Quigley ME, Sheehan KL, Casper RF, Yen SSC. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma. J Clin Endocrinol Metab 1980;50:427-30.
39. Aono T, Miyake A, Yasuda T, Kolke K, Kurachi K. Restoration of estrogen positive feedback on LH release by bromocriptine in hyperprolactinemic patients with galactorrheaamenorrhea. Acta Endocrinol (Copenh) 1979;91:591-600.
40. Magoffin DA, Erickson GF. Prolactin inhibition of luteinizing hormone-stimulated androgen synthesis in ovarian interstitial cells cultured in defined medium: mechanism of action. Endocrinology 1982;111:2001-7.
41. Wang C, Hsueh AJW, Erickson GF. Prolactin inhibition of estrogen production by cultured rats granulosa cells. Mol Cell Endocrinol 1980;20:135-44.
42. Katz E, Adashi EY. Hyperprolactinemic disorders. Clin Obstet Gynecol 1990;33:622-39.
43. Boulanger CM, Mashchak CA, Chang RJ. Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine. Fertil Steril 1985;44:532-5.
44. Speroff L, Glass RH, Kase NG. Amenorrhea. In: Mitchel C, editor. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore: Williams & Wilkins, 1994:401-56.
45. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304:156-8.
46. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67-71.
47. Kletzky OA, Davajan V. Hyperprolactinemia, diagnosis and treatment. In: Mishell DR, Davajan V, Lobo RA, editors. Infertility, contraception and reproductive endocrinology. 3rd ed. Boston: Blackwell Scientific Publications, 1991:396-421.
48. Honbo KS, van Herle AJ, Kellet KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978;64: 782-7.
49. Richardson GS. Reflex lactation (thoracotomy) and reflex ovulation (intercostal block): case report, review of the literature, and discussion of mechanism. Obstet Gynecol Surv 1970;25:1021-36.
50. Stanisic TH, Donova J. Prolactin secreting renal cell carcinoma. J Urol 1986;136:85-6.
51. Hoffman WH, Gala RR, Kovacs K, Subramanian MG. Ectopic prolactin secretion from a gonadoblastoma. Cancer 1987;60:2690-5.
52. Kallenberg GA, Pesce CM, Norman B, Ratner RE, Silvergerg SG. Ectopic hyperprolactinemia resulting from an ovarian teratoma. JAMA 1990;263:2472-4.
53. Murdoch AP, Dunlop W, Kendall-Taylor P. Studies of prolactin secretion in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1986;24:165-75.
54. Kolodny RC, Jacobs LS, Daughaday WH. Mammary stimulation causes prolactin secretion in non-lactating women. Nature 1972;238:284-6.
55. Lyons WR, Li CH, Johnson RE. The hormonal control of mammary growth and lactation. Recent Prog Horm Res 1958;14:219-54.
56. Dehoff MH, Elgin RG, Collier RJ, Clemmons DR. Both type I and II insulin-like growth factor receptor binding increase during lactogenesis in bovine mammary tissue. Endocrinology 1988;122:2412-7.
57. Hadsell DL, Campbell PG, Baumrucker CR, Characterization of the change in type I and II insulin-like growth factor receptor of bovine mammary tissue during the pre-and post-partum periods. Endocrinology 1990;126:637-43.
58. Weitzman RE, Firemark HM, Glatz TH, Fisher DA. Thyrotropin-releasing hormone stimulates release of arginine-vasopressin and oxytocin in vivo. Endocrinology 1979;104: 904-7.
59. Shyamala G. Specific cytoplasmic glucocorticoid hormone receptors in lactating mammary glands. Biochemistry 1973; 12:3085-90.
60. Frantz AG, Wilson JD: Endocrine disorders of the breast. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia: W.B. Saunders Company, 1992:953-75.
61. Kleinberg DL, Todd J, Babitsky G, Greising J. Estradiol inhibits prolactin induced α-lactalbumin production in normal primate mammary tissue in vitro. Endocrinology 1982; 110:279-81.
62. Noel GL, Suh HK, Frantz AG. Prolactin release during nursing and breast stimulation in postpartum and nonpostpartum subjects. J Clin Endocrinol Metab 1974;38:413-23.
63. Johnston JM, Amico JA. A prospective longitudinal study of the release of oxytocin and prolactin in response to infant suckling in long term lactation. J Clin Endocrinol Metab 1986;62:653-7.
64. Scott JZ, Kletzky OA, Brenner PF, Mishell DR Jr. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function. Fertil Steril 1978;30:141-5.
65. Poretsky L, Garber J, Kleefield J. Primary amenorrhea and pseudoprolactinoma in a patient with primary hypothyroidism. Am J Med 1986;81:180-2.
66. Kleinberg DL, Noel CL, Frantz AG. Galactorrhea: a study of 235 cases including 48 with pituitary tumors. N Engl J Med 1977;296:589-600.
67. Schlechte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors. Endocr Rev 1980;1:295-308.
68. Ho Yuen B. Etiology and treatment of hyperprolactinemia. Semin Reprod Endocrinol 1992;10:228-35.
69. Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983;56:1120-3.
70. Klibanski A, Biller BMK, Rosenthal DI, Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67:124-30.
71. Carman JS, Wyatt RJ. Reduction of serum-prolactin after subcutaneous salmon calcitonin. Lancet 1977;1:1267-8.
72. Pahuja D, DeLuca H. Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. Science 1981;214:1038-9.
73. Dwyer AJ, Frank JA, Doppman JL, et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology 1987; 163:421-6.
74. Davis PC, Huffman JC Jr, Spencer T, Tindall GT, Braun IF MR imaging of pituitary adenoma: CT, clinical and surgical correlation. AJR 1987;148:797-802.
75. Vance ML, Thorner MO. Prolactinomas. Endocrinol Metab Clin North Am 1987;16:731-53.
76. Aisaka K, Yoshida K, Mori H. Analysis of clinical back-grounds and pathogenesis of luteal-phase defect. Horm Res 1992;37 Suppl 1:41-7.
77. Ylikorkala O, Kauppila A. The effects on the ovulatory cycle of metoclopramide-induced increased prolactin levels during follicular development. Fertil Steril 1981;35:588-9.
78. Glass RH. Infertility. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology. 3rd ed. Philadelphia: W.B. Saunders, 1991:689-709.
79. Farine D, Dor J, Lupovici N, Lunenfeld B, Mashiach S. Conception rate after gonadotropin therapy in hyperprolactinemia and normoprolactinemia. Obstet Gynecol 1985;65: 658-60.
80. Frantz AG, Kleinberg DL, Noel GL. Studies on prolactin in man. Recent Prog Horm Res 1972;28:527-90.
81. Fahy UM, Foster PA, Torode HW, Hartog M, Hull MG. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992;6:183-8.
82. Pituitary Adenoma Study Group. Pituitary adenomas and oral contraceptives: a multicenter case-control study. Fertil Steril 1983;39:753-60.
83. Loriaux DL, Wild RA. Contraceptive choices for women with endocrine complications. Am J Obstet Gynecol 1993;168: 2021-6.
84. Vance ML, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med 1984;100:78-91.
85. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-8.
86. Lamberts SWJ, Quik RFP. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72:635-41.
87. Ellis PM, Gartside SE, Ware CJ, Campling GM, Cowen PJ. Does metergoline selectively attenuate 5-HT mediated prolactin release? Psychopharmacology 1991;105:129-31.
88. Vazquez JE, Vazquez CM. Treatment of the hyperprolactinemic states with lisuride in a simple open study. Ginecol Obstet Mex 1991;59:202-5.
89. Brue T, Pellegrini I, Gunz G, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577-84.
90. Katz E, Weiss BE, Hassell A, Schran HF, Adashi EY. Increased circulating levels of bromocriptine after vaginal compared to oral administration. Fertil Steril 1991;55:882-4.
91. Schettini G, Lombardi G, Merola B, et al. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-actin bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf) 1990;33:161-9.
92. Lengyel A-MJ, Mussio W, Imamura P, Vieira JGH, Lancranjan I. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas. Fertil Steril 1993;59:980-7.
93. Kletzky OA, Marrs RP, Davajan V. Management of patients with hyperprolactinemia and normal or abnormal tomograms. Am J Obstet Gynecol 1983;147:528-32.
94. Mori H, Mori S, Saitoh Y, et al. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Cancer 1985;56: 230-8.
95. Faglia G, Moriondo P, Travagloni P, Giovanelli MA. Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet 1983;1:133-4.
96. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877-901.
97. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983;309:280-3.
98. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457-62.
99. Horvath E, Kovacs K. Gonadotroph adenomas of the human pituitary: sex-related fine-structural dichotomy. A histologic, immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol 1984;117:429-40.
100. Smallridge RC. Thyrotropin-secreting pituitary tumors. Endocrinol Metab Clin North Am 1987;16:765-92.